The COVID-19 pandemic is still a serious burden on the healthcare system worldwide, despite the availability of vaccines. For moderately to severely ill patients, the treatment options are limited, and very little innovation has found its way into the clinical practice (1).
Endothelial dysfunction leads to vascular leakage and is a consequence of critical diseases such as COVID-19 and sepsis. The biomarker bio-ADM allows the assessment of endothelial function.
Point of care testing for rapid results
The multicenter study plans to enroll more than 200 hospitalized patients with moderate to severe COVID-19 disease for randomized treatment with either Adrecizumab or placebo on top of current standard of care. The biomarker measurements are performed using SphingoTec’s rapid point of care platform.
(3) Laterre PF, et al. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial. Intensive Care Med. 2021 Nov;47(11):1284-1294. doi: 10.1007/s00134-021-06537-5.
(4) Varga et al. Endothelial cell infection and endothelitis in COVID-19. The Lancet, 2020, DOI: doi.org/10.1016/S0140-6736(20)30937-5
(5) van Lier et al 2020, Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3, J. Intern. Med., DOI: doi.org/10.1111/joim.13220
(6) Simon T-P et al. Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study. Journal of Clinical Medicine. 2021, 10, 1667. doi.org/10.3390/jcm10081667